Background {#Sec1}
==========

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, occurring in 85--90% of lung cancer cases \[[@CR1]\], and includes adenocarcinoma (40% of all lung cancers), squamous cell carcinoma (25--30%) and large cell carcinoma (10--15%) \[[@CR2]\]. NSCLC is staged according to the American Joint Committee on Cancer/Union for International Cancer Control system \[[@CR3]\], and measurement of lesions follows the Response Evaluation Criteria in Solid Tumors (RECIST) \[[@CR4]\]. Approximately 40% of patients will have metastatic NSCLC (mNSCLC) at diagnosis \[[@CR5]\], which includes cancers found in the lung and in the lymph nodes in the middle of the chest (defined as stage IIIA and IIIB; no distant metastasis), and cancers that have spread to both lungs or to another part of the body (defined as stage IV; distant metastasis) \[[@CR6], [@CR7]\].

Treatment is recommended according to the stage of mNSCLC, but treatment options are limited in the later stages of disease \[[@CR7], [@CR8]\]. Five-year survival rates are considerably lower in later than in earlier stages of NSCLC (stage IA, 45%; stage IIIA, 14%; stage IIIB, 5%; stage IV, 1%) \[[@CR9]\]. Moreover, symptoms such as coughing and wheezing, chest pain, hoarseness and weight loss can severely reduce functional independence in patients with mNSCLC \[[@CR10], [@CR11]\]. Patient-reported health-related quality of life (HRQoL) provides an overall evaluation of health, well-being and daily functioning, and is impaired in patients with mNSCLC owing both to the disease and to treatment sequelae. Maintenance or improvement of HRQoL is an important treatment goal \[[@CR12]\].

HRQoL can be expressed as a health state utility value (HSUV) ranging from 0 (death) to 1 (full health). If the health state is considered to be worse than death, health states can be valued at less than 0. Utility values are key drivers in cost-effectiveness analyses because estimates of quality-adjusted life-years (QALYs) are obtained by multiplying HSUVs for each health state by the time spent in that health state. Estimates of cost per QALY are highly sensitive to the choice of HSUV. It is therefore important to identify specifically those HSUVs that have been derived using methods acceptable to health technology assessment (HTA) authorities \[[@CR13]\].

HSUVs can be derived using a range of instruments and techniques \[[@CR14], [@CR15]\]. In brief, instruments include: generic preference-based measures such as the EQ-5D-3 L \[[@CR16]\] or EQ-5D-5 L \[[@CR17]\], Health Utilities Index (HUI) \[[@CR18]\], 6-dimension Short-Form Health Survey (SF-6D) \[[@CR19]\], Assessment of Quality of Life instrument (AQoL) \[[@CR20]\], 15-dimensional HRQoL measure \[[@CR21]\], Quality of Well-Being scale \[[@CR22]\], and multi-attribute utility instrument; as well as directly elicited standard gamble (SG), time trade-off (TTO) and visual analogue scale (VAS, e.g. EuroQoL VAS \[EQ-VAS\]). Mapping algorithms may also be used to convert values obtained from a condition-specific questionnaire to a generic preference-based measure; or to convert data from the 12- or 36-item Short-Form Health Survey (SF-12 or SF-36) to SF-6D \[[@CR23]\]. Techniques may vary in terms of whose health is being measured (a patient's or a caregiver's), who responds to the questionnaire or, if using vignettes, who considers the health-state description (the patient regarding their own health, a patient with a different disease, the patient's closest caregiver, another caregiver, a physician or another healthcare provider). For preference-based measures, variation can stem from who values the health state (e.g. UK general population sample) and which choice-based method is used in this valuation (SG or TTO).

HTA bodies including the UK National Institute for Health and Care Excellence (NICE) \[[@CR24], [@CR25]\], the Scottish Medicines Consortium (SMC) \[[@CR26]\], the Canadian Agency for Drugs and Technologies in Health (CADTH) \[[@CR27]\], the French Haute Autorité de Santé (HAS) \[[@CR28]\] and the Australian Pharmaceutical Benefits Advisory Committee (PBAC) \[[@CR29]\] have stated preferences for HSUV methodology. Across these agencies, there is a preference for HSUVs estimated using generic preference-based measures. NICE has a strong preference for EQ-5D, as this reduces variability induced when different instruments are used between different disease areas. Agencies also strongly prefer patients to be the respondents, as patients can best describe their own health state. Finally, valuation estimated using a country-specific general-population tariff via a choice-based elicitation technique such as SG or TTO is preferred, as this represents societal preferences.

This systematic review had three main aims: first, to identify HSUVs for adults with previously treated mNSCLC, by treatment line and health state, and to evaluate the relevance of each health state to patients, for example, line of treatment, adverse events (AEs), response status and prognostic factors; second, to identify relevant disutilities or utility decrements associated with adverse events (irrespective of line of treatment or health state). Finally, the suitability of the HSUVs according to HTA reference case was explored and the quality of the HSUVs assessed.

Methods {#Sec2}
=======

Study design and search strategy {#Sec3}
--------------------------------

A systematic review of HSUVs in mNSCLC was undertaken to identify HSUV studies in any treatment line. Studies, published either as full papers or as conference abstracts, in patients previously treated for mNSCLC were selected for further analysis. The following databases were searched: Embase (1974 to 7 September 2016); MEDLINE® (1966 to 7 September 2016); MEDLINE In-Process and e-publications ahead of print (database inception to 7 September 2016); and the Cochrane Library (including the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, the Cochrane Central Register of Controlled Trials, the National Health Service Economic Evaluation Database and the HTA database; 1968 to 7 September 2016).

Search strings are summarized in Additional file [1](#MOESM1){ref-type="media"}: Table S1, and were constructed not only to find utilities in mNSCLC (using a wide range of NSCLC and mNSCLC terms combined with the HSUV filter adapted from Arber et al. 2015 \[[@CR30]\]) but also to identify all relevant disutilities or utility decrements associated with AEs/comorbidities. To ensure that estimates would be available from previously treated mNSCLC populations for all AEs or comorbidity health states relevant to the experience of such patients, the strings were designed to search for disutilities or decrements from a broader group of populations, as follows: from lung cancer; for progressive disease disutilities from advanced/metastatic cancer; for disutilities associated with the most common sites of metastasis from the lung (bone, respiratory system, nervous system, adrenal gland and liver) from advanced cancer; for disutilities associated with AEs or toxicities of cancer therapy; and disutilities associated with specific grade 3--4 AEs known to occur with cancer treatments from advanced cancer populations (pneumonia, pneumonitis, increased aspartate aminotransferase, febrile neutropenia, neutropenia, infection, sepsis, fatigue, lethargy, nausea, vomiting, ulcers, stomatitis, gastrointestinal disturbance, diarrhoea, visual disturbance, hearing loss, hair loss, psychological/self-esteem changes, rash, anaemia, bleeding and hypertension). From the identified disutilities/decrements for each AE/co-morbidity health state, those from the most relevant population available could be selected following an order of decreasing population specificity from first-line mNSCLC to NSCLC, lung cancer and advanced/metastatic cancer (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Studies reporting adverse event health state (dis) utilities by patient population and country. *Abbreviations: 1L* first line, *2L* second line, *BC* breast cancer, *BM* bone metastasis, *Hb* haemoglobin, *i.v.* intravenous, *LC* lung cancer, *LNS* line of treatment not specified, *mLC* metastatic lung cancer, *mNSCLC* metastatic non-small cell lung cancer, *NICE* National Institute for Health and Care Excellence, *NSCLC* non-small cell lung cancer, *SCLC* small cell lung cancer, *SRE* skeletal-related event

Using the term "NSCLC" or "non-small cell lung cancer", manual searching of the EQ-5D website, of the School of Health and Related Research Health Utilities Database (ScHARRHUD) and of major pharmacoeconomic and clinical conferences in 2015--2016 was conducted on 3 and 5 December 2016. Conferences included: the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) International Meetings and European Congresses; the HTA International Annual Meetings (HTAi); the Society for Medical Decision Making (SMDM) North American Meetings and European Conferences; the American Society of Clinical Oncology (ASCO) Meetings; and the European Society for Medical Oncology (ESMO) Congresses. Bibliographic reference lists of relevant systematic reviews from 2010 onwards were searched and of relevant cost-utility analyses, and HTA reports from various bodies identified in a parallel economic systematic review, including: NICE; SMC; All Wales Medicines Strategy Group (AWMSG); PBAC; CADTH; Institut National d'Excellence en Santé et en Services Sociaux; pan-Canadian Oncology Drug Review (pCODR); and HAS.

The PICOS (patient, intervention, comparator, outcome, study) statements for study inclusion and exclusion criteria are summarized in Table [1](#Tab1){ref-type="table"}. Although, second- and later-line data were of primary interest, studies that reported utilities for patients with mNSCLC who were either treatment-naïve or in receipt of maintenance first-line treatment were included for reference at the first screening but data were not extracted. These studies are listed in Additional file [2](#MOESM2){ref-type="media"}: Table S2.Table 1Inclusion criteriaCharacteristicInclusion criteriaExclusion criteriaPopulationAdult patients (aged ≥16 years)\
Locally advanced NSCLC or mNSCLC, second/subsequent line\
Locally advanced or metastatic NSCLC, line unspecifiedPopulation not of interest, e.g.\
• in vitro data\
• animal data\
• mixed adult/child population or child population\
• mixed disease populations without mNSCLC data reported separately\
• not disease of interest\
• 1 L mNSCLC data (treatment-naïve or maintenance first-line treatment) were excluded but tagged^a^Interventions/comparatorsNot relevant for QoL SR selection. Intervention-specific utility data were noted as such during data extractionN/AOutcomesFor mNSCLC patients:\
• individual (patient or caregiver) derived mean or median health state utilities from indirect generic HRQoL measure (EQ-5D (-3 L and -5 L), SF-6D, HUI2, HUI3, AQoL, QWB, 15D, MAUI) or direct valuation by TTO, SG or EQ-VAS\
• SF-36 or SF-12\
• general public valuations of vignettes using TTO or SG\
For NSCLC or wider population:\
• disutilities or decrements for AEs^b^ or progressive diseaseNo outcome of interest:\
• expert or healthcare provider (doctor, nurse) valuations of utilities\
• utilities not relating to a specific health stateStudy designRCTs, non-RCTs, observational dataStudy design not of interest:\
• case reports, *n* = 1 before-and-after studies\
• PK/PD study only\
• (Non-systematic) reviews\
• SRs/NMAs^c^Date limitsUnlimited--Child citationCitation linked to another paper but with unique dataChild citation or sub-study with no unique data, determined at first or second passDuplicate citationDuplicate/copyPublication typePublication type not of interest e.g. editorials, commentaries, letters, notes, press articles, unless relevant data has been published in a letter, for example, that does not appear elsewhere in the literature\
Confidential reports where unable to use report, or Hayes Inc. reports requiring purchaseLanguageEnglish or French\
Any foreign language paper with an English abstract were included if sufficient information is present in the English abstract to ensure the eligibility criteria are metFull text in language other than English or French with no English abstract or no abstract; or insufficient information in English language abstract of foreign language full paper to assess eligibility^a^To enable listing in the report^b^Disutilities may be included for AEs, inconvenience of treatment or progressive health states from diseases outside NSCLC (preferably from lung cancer or from advanced/metastatic cancer) where no such data are available from patients with NSCLC^c^SRs were kept in until the second pass, where the full paper's included studies were examined, after which the SR itself was excluded*Abbreviations*: *1 L* first line, *3 L* 3-level, *5 L* 5-level, *15D* 15-dimensional health-related quality of life measure, *AE* adverse event, *AQoL* Assessment of Quality of Life instrument, *EQ-VAS* EuroQoL visual analogue scale, *HRQoL* health-related quality of life, *HUI2/3* Health Utilities Index Mark 2/3, *MAUI* multi-attribute utility instrument, *mNSCLC* metastatic non-small cell lung cancer, *N/A* not available, *NMA* network meta-analysis, *NSCLC* non-small cell lung cancer, *PD* pharmacodynamic, *PK* pharmacokinetic, *QoL* quality of life, *QWB* Quality of Well-Being scale, *RCT* randomized controlled trial, *SF-6D* 6-dimension Short-Form Health Survey, *SF-12/36* 12/36-item Short-Form Health Survey, *SG* standard gamble, *SR* systematic review, *TTO* time trade-off*, VAS* visual analogue scale

Mapping from condition-specific to preference-based studies was not sought because it was anticipated that sufficient published utility and EQ-5D data would be available to populate the health states of an economic model, and because results based on mapping algorithms sit lower in the acceptance hierarchy used by some HTA authorities (Additional file [3](#MOESM3){ref-type="media"}: Figure S1). We have acknowledged NICE's stated preference for EQ-5D-3 L data over EQ-5D-5 L (Additional file [3](#MOESM3){ref-type="media"}: Figure S1) and provide detailed information of the instrument used for generating data for each identified study in Table [2](#Tab2){ref-type="table"} \[[@CR31]\].Table 2Identified utility studies by line of treatmentAuthor, year, countryLine of treatmentHealth stateInstrumentTreatmentFirst line^a^ Handorf 2012 USA \[[@CR70]\]1 LStage IV adenocarcinoma SDis, PD, SDis+AEs (neutropenia, pneumothorax, haemorrhage, thrombocytopenia, thrombosis)Expert opinion estimates,^b^ published sourcesNTS Nafees 2016 Multinational and UK \[[@CR68]\]1 LMetastatic NSCLC common grade III/IV toxicities (neutropenia, febrile neutropenia, fatigue, nausea and vomiting, diarrhea, hair loss, rash), bleeding, hypertensionTTO (general public)NTS≥ First line^c^ Chevalier 2013 France and nine other countries \[[@CR38]\]1 L, 2 L, 3/4 L and BSCAdvanced/metastatic NSCLC 1 L, 2 L, 3/4 L PF and PDEQ-5DNTS Chouaid 2013 Multinational \[[@CR39]\]1 L 55.1%\
2 L 24.7%\
3/4 L 17.9%\
BSC 2.3%Advanced/metastatic NSCLC 1 L, 2 L, 3/4 L, BSC and mixed line PF and PDEQ-5D, EQ-VASNTS Iyer 2013 France, Germany \[[@CR46]\]1 L 52%\
2 LL 48%Advanced/metastatic NSCLCEQ-5DNTSSecond line Blackhall 2014 Multinational \[[@CR41]\]2 L after progression on platinum-based 1 L therapyLocally advanced/metastatic ALK+ NSCLC BL and treatment-specific utilities (not PSS)EQ-5D EQ-VASCRZ\
PEM\
DOC Huang 2016 Worldwide \[[@CR45]\]2 L after platinum-based therapyAdvanced PD-L1+ NSCLC NTS PF, PD\
NTS time to deathEQ-5DPEMB\
DOC Langley 2013 UK, Australia \[[@CR48]\]2 L^d^Treatment-specific stage IV NSCLC with BM at BL and after certain time points on treatmentEQ-5DOSC\
WBRT + OSC Nafees 2008 UK \[[@CR69]\]2 LMetastatic NSCLC PD, RES, SDis, common grade III/IV toxicities (neutropenia, febrile neutropenia, fatigue, nausea and vomiting, diarrhea, hair loss, rash)SG (general public)NTS Novello 2015 Multinational \[[@CR49]\]2 LStage III/IV recurrent NSCLC (SQ and NSQ) treatment-specific at BL and certain time points on treatment (≤ 30 weeks)EQ-5D, EQ-VASNIN + DOC\
PLA + DOC Reck 2015 Multinational \[[@CR50]\]2 LAdvanced SQ NSCLC treatment-specific at BL reported. Collected also for up to 1 year but values NR in abstractEQ-5D, EQ-VASNIVO\
DOC Rudell 2016 USA, Canada, Hong Kong, Italy, Japan, Republic of Korea, Spain, Taiwan \[[@CR57]\]2 LAdvanced EGFR+ NSCLC, treatment-specific at BL and 36 weeks on OSIEQ-VASOSI Schuette 2012 Germany, Austria \[[@CR51]\]2 LStage III/IV NSCLC treatment-specific at BL, 6 weeks (second cycle) and sixth cycleEQ-5D\
EQ-VASPEM Vargas 2009 Mexico \[[@CR72]\]2 L after previous CHEMONSCLC, stage NR (assumed advanced), treatment-specific not PSSGlobal QoL indexERL\
Taxanes≥ Second line Chen 2010 UK/multinational \[[@CR64]\]2 L, 3 L and BSCStage IIIb/IV EGFR+ NSCLC treatment-specific (not PSS)\
On/after DOC 2 L\
On/after PEM 2 L\
On ERL 3 L BSCSG (general public)DOC\
PEM\
ERL\
BSC Griebsch 2014 Multinational \[[@CR37]\]2LL^e^ and treatment-naïveStage IIIb with pleural effusion or stage IV NSCLC adenocarcinoma treatment-specific and NTS effect of progressionEQ-5D, EQ-VASAFA\
BSC\
CIS/PEM Hirsh 2013 Multinational \[[@CR40]\]2LL^f^Stage IIIb/IV NSCLC BL and treatment-specific on oral AFA 50 mg q.d. + BSC or PLA + BSCEQ-5DAFA + BSC\
PLA + BSC Stewart 2015 Canada \[[@CR56]\]Targeted therapy 84%\
3LL 25%\
RCT 22%Metastatic EGFR+ NSCLC, all patients not PSS\
PR/SDis EGFR TKI\
RES CHEMO\
RES GEF\
RES ERL\
RES OSI\
PD EGFR TKIEQ-5D-3 LGEF\
ERL\
OSI Schwartzberg 2015 USA, Canada \[[@CR60]\]2 LLSquamous and non-squamous stage IIIb/IV NSCLC treatment-specific weeks 6--30\
Treatment-specific PR, SDis and PD weeks 6--30EQ-VASNIVOTreatment line not specified Bradbury 2008 Canada \[[@CR42]\]UnclearAdvanced NSCLC Treatment-specific (not PSS)EQ-5DERL\
BSC Chang 2016 South Korea \[[@CR63]\]NRAdvanced NSCLC from \> 360 days before death to \< 30 days before death (not PSS)TTO (general public)NTS Dansk 2016 UK \[[@CR43]\]NRSynthesized advanced NSCLC PF, PD used in NICE HTAs\
Trial-based PF, PD\
Non-trial based PF, PDEQ-5DNTS Doyle 2008 UK \[[@CR65]\]NRMetastatic NSCLC SDis, RES, severe symptoms (cough, dyspnoea, pain)SG (general public)NTS Grunberg 2009 USA \[[@CR58]\]NRMixed cancer population chemotherapy-related nausea, vomiting, and nausea and vomiting, of different severitiesSG (patient)CHEMO Grutters 2010 Netherlands \[[@CR44]\]NRNSCLC with grade 3+ dyspnoeaEQ-5DNTS Jang 2010 Canada \[[@CR47]\]NRStage IV NSCLC and locally advanced NSCLCEQ-5DNTS Linnet 2015 Denmark \[[@CR62]\]UnclearMetastatic NSCLC second and third CHEMO cycles on oral VINO\
Patient and caregiver utilities reportedSF-12VINO Lloyd 2005 UK \[[@CR66]\]NRStage IV NSCLC RES, SDis i.v. treatment, SDis oral treatment, PD, end of lifeSG (general public)NTS Lloyd 2008 \[[@CR59]\]Previous CHEMOAnaemia by haemoglobin levelGeneral public SG, patient TTONTS Manser 2006 Australia \[[@CR61]\]NRStage IV NSCLCAQoLNTS Matza 2014 UK and Canada \[[@CR67]\]NRStage IV cancer with BMs and different types of SRE (spinal cord compression with/without paralysis, fracture of leg, fracture of rib, fracture of arm), radiation treatment (2 weeks, 5 appointments/week), radiation treatment (2 appointments), surgery to stabilize boneTTO (general public)NTS Tabberer 2006 UK \[[@CR52]\]NRAdvanced NSCLC RES, SDis, SDis oral treatment, SDis i.v. treatment, PD, near death, AEs (neutropenia, febrile neutropenia, nausea, diarrhoea, rash, stomatitis, neuropathy)EQ-5D (general public)NTS Trippoli 2001 Italy \[[@CR53]\]NRMetastatic NSCLCEQ-5D, EQ-VASNTS Westwood 2014 \[[@CR71]\]NR for other disutilitiesAdvanced NSCLC\
Disutility for anaemia and for i.v./oral treatment modeSG NR for other disutilitiesNTS\
ERL\
i.v. tx Yang 2014 Taiwan \[[@CR54]\]NRNSCLC operable (I--IIIA) and NSCLC inoperable (IIIB/IV)EQ-5DNTS Yokoyama 2013 Japan \[[@CR55]\]NRStage IIIB/IV mixed NSCLC/SCLC with bone metastasis and SRE (pathologic fracture, radiation or surgery to bone lesion, spinal cord compression or hypercalcaemia)EQ-5DNTS^a^Studies were retained, despite reporting first-line treatment only, because they reported progressive disease utility estimates similar to those seen in a second-line population, or reported AE disutility estimates from populations broader than mNSCLC^b^Although the utilities were based on expert opinion, these were retained, as they provide disutility estimates for the adverse events pneumothorax, thrombocytopenia and thrombosis, not available elsewhere^c^Studies reported data on first-line treatment and subsequent treatment lines^d^Previous treatment with systemic CHEMO or EGFR inhibitors allowed^e^Lux-Lung 1 trial data were in patients progressed on 1--2 lines of treatment, one of which was platinum based (could include adjuvant setting treatment line), and had PD after at least 12 wks of ERL or GEF. Lux-Lung 3 trial data were in treatment-naïve patients, so not 2 L.^f^Progressed on 1--2 lines of treatment, one of which was platinum based, and had PD after at least 12 wks of ERL or GEF*Abbreviations: 1 L* first line, *2 L* second line, *2 LL* second and subsequent line, *3LL* third and subsequent line, *3/4 L* third and fourth line, *AE* adverse event, *AFA* afatinib, *AQoL* Assessment of Quality of Life instrument, *BL* baseline, *BM* bone metastasis, *BSC* best supportive care, *CHEMO* chemotherapy, *CIS* cisplatin, *CRZ* crizotinib, *DOC* docetaxel, *EGFR* epidermal growth factor receptor, *EQ-VAS* EuroQol visual analogue scale, *ERL* erlotinib, *GEF* gefitinib, *GEM* gemcitabine, *i.v.* intravenous, *NIN* nintedanib, *NIVO* nivolumab, *NR* not reported, *NSCLC* non-small cell lung cancer, *NSQ* non-squamous, *NTS* not treatment-specific, *OSC* optimal standard care, *OSI* osimertinib, *PD* progressive disease, *PEM* pemetrexed, *PEMB* pembrolizumab, *PF* progression-free, *PLA* placebo, *PR* partial response, *PSS* progression-status-specific, *q.d.* once daily, *QoL* quality of life, *RCT* randomized controlled trial, *RES* response, *SCLC* small cell lung cancer, *SDis* stable disease, *SF-12* 12-item Short--Form Health Survey, *SG* standard gamble, *SRE* skeletal-related event, *TKI* tyrosine kinase inhibitor, *TTO* time trade-off, *VAS* visual analogue scale, *VINO* vinorelbine, *WBRT* whole-brain radiotherapy

Study selection {#Sec4}
---------------

The screening process complied with the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR32]\]. Publications were de-duplicated using EndNote (Clarivate Analytics, Philadelphia, PA, USA) and using Rayyan (Qatar Computing Research Institute, Doha, Qatar) \[[@CR33]\], an internet-based reference management system endorsed as suitable for systematic review screening by the European Network for HTA \[[@CR34]\]. Abstracts and titles of papers were screened by one reviewer, and a 50% sample check conducted by a second reviewer; exclusion criteria are summarized in Table [1](#Tab1){ref-type="table"}. The full texts of papers potentially meeting the selection criteria were screened by one reviewer, and a 50% sample check was conducted by a second reviewer. Discrepancies were discussed between reviewers, and any unresolved disputes were referred to a third reviewer.

Data extraction {#Sec5}
---------------

Data were collected using a piloted data-extraction sheet. Extraction was conducted by one reviewer, and priority data elements were quality checked by a second reviewer. The information extracted included study design, whether the selection criteria yielded a population that matched the target population (i.e. previously treated adult patients with mNSCLC), health state description, instrument type, instrument scale, HSUV or (dis) utility or decrement estimates and measure of variability (median with interquartile range or mean with standard error, standard deviation or 95% confidence interval), derivation methods and if the data presented were appropriate for use in HTA submissions to NICE, SMC, CADTH, HAS and PBAC.

Quality and relevance assessment {#Sec6}
--------------------------------

The appropriateness of utilities reported for use in economic evaluations was determined by whether data met the requirements of the HTA body reference case; and the quality of utility estimates (based on sample size, response to the questionnaire, loss to follow-up, handling of missing data, and reporting of point and variance estimates, as discussed in NICE Decision Support Unit Technical Support Document 11 and its related publication \[[@CR25], [@CR35]\]; Additional file [4](#MOESM4){ref-type="media"}: Table S3). Any recommendation for, or rationale against, the use of specific utilities in a cost--utility analysis model in previously treated patients with mNSCLC was also taken into consideration in line with preliminary guidance from the ISPOR Health State Utility Good Practices Task Force \[[@CR36]\].

Results {#Sec7}
=======

Search yields {#Sec8}
-------------

Electronic database searches identified 1883 citations (1521 from MEDLINE/Embase, 144 from MEDLINE In-Process/e-publications and 218 from the Cochrane Library databases). After de-duplication (51 citations: 30 via Endnote and 21 via Rayyan) and title/abstract screening (1557 exclusions), 275 full-text papers were reviewed. Of these, 250 were excluded (21 of which were tagged as reporting first-line treatment; Additional file [2](#MOESM2){ref-type="media"}: Table S2), yielding 25 citations that were included from electronic sources. Manual searching identified 11 citations. In total, 36 articles were included, reporting 34 studies (Table [2](#Tab2){ref-type="table"}). Two articles \[[@CR37], [@CR38]\] were linked to other publications \[[@CR39], [@CR40]\], and were retained because they provided additional information. The study selection is summarized in a PRISMA flow chart in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2PRISMA flow chart for study selection. *Abbreviation: PRISMA* Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Description of studies identified {#Sec9}
---------------------------------

Among the 36 articles (34 studies) identified, 19 reported EQ-5D scores \[[@CR37]--[@CR55]\] (three studies further specified the instrument as EQ-5D-3 L \[[@CR39], [@CR41], [@CR56]\] and two as EQ-5D-5 L \[[@CR44], [@CR57]\]; Table [2](#Tab2){ref-type="table"}), two reported SG or TTO directly elicited from patients \[[@CR58], [@CR59]\], two reported EQ-VAS scores only \[[@CR57], [@CR60]\], and one reported AQoL scores \[[@CR61]\] (Table [2](#Tab2){ref-type="table"}). Moreover, one study reported SF-12 scores for caregivers to patients with mNSCLC \[[@CR62]\], eight reported HSUVs from valuations of vignettes made by members of the public using SG or TTO \[[@CR59], [@CR63]--[@CR69]\] (one of which reported both general public-elicited SG and patient-elicited TTO) \[[@CR59]\], and one reported disutility estimates based on expert opinion for pneumothorax, thrombocytopenia and thrombosis, adverse event health states for which disutilities were not available from other HSUV derivation methods \[[@CR70]\]. A further two articles reported HSUVs but were unclear about how these were derived; one reported disutilities used in previous NICE submissions, for anaemia and for oral and intravenous treatment modes \[[@CR71]\], and one reported a "global quality of life index" for second-line NSCLC \[[@CR72]\].

Among the dataset, two studies were retained despite reporting first-line treatment only, because they reported AE disutility estimates from populations broader than mNSCLC \[[@CR68], [@CR70]\]; three further studies that reported first-line data also reported on subsequent treatment lines \[[@CR38], [@CR39], [@CR46]\]. Eleven studies focused exclusively on HSUVs associated with second-line treatment \[[@CR41], [@CR45], [@CR48]--[@CR51], [@CR57], [@CR59], [@CR69], [@CR71], [@CR72]\], and five reported HSUVs in second-line and subsequent treatment \[[@CR37], [@CR40], [@CR56], [@CR60], [@CR73]\]. Line of treatment was unspecified in 15 studies \[[@CR42]--[@CR44], [@CR47], [@CR52]--[@CR55], [@CR58], [@CR61]--[@CR63], [@CR65]--[@CR67]\].

Relevant HSUVs by line of treatment {#Sec10}
-----------------------------------

Utilities were reported for a range of health state types: treatment-specific or not, RECIST response-based or not, time-on-treatment, time-till-death, or a combination of these. Details of HSUV estimates by treatment line are given in Table [3](#Tab3){ref-type="table"}. Among patients receiving second-line or subsequent treatment for advanced NSCLC or mNSCLC, mean HSUV estimates based on EQ-5D for stable/progression-free disease and for patients at baseline or pre-treatment were in the range 0.66--0.76 \[[@CR38], [@CR39], [@CR41], [@CR45], [@CR49], [@CR50]\]; in the same group, mean values for patients with progressive disease were generally lower (0.55--0.69) \[[@CR38], [@CR39], [@CR45]\]. Among patients on treatment at this stage of disease and treatment line, the range of mean HSUVs based on EQ-5D was broad (0.53--0.82) \[[@CR40], [@CR41], [@CR46], [@CR51], [@CR56]\], the highest value being associated with treatment with tyrosine kinase inhibitors \[[@CR41], [@CR56]\]. A similar range of HSUV values was seen among patients being treated for advanced NSCLC or mNSCLC when the treatment line was unspecified (0.53--0.77) \[[@CR42], [@CR47], [@CR52], [@CR53]\]. Only three papers specified using EQ-5D-3 L \[[@CR39], [@CR41], [@CR56]\] and only two EQ-5D-5 L \[[@CR44], [@CR57]\].Table 3Health state utility values by treatment line, health state and instrumentStudyHealth stateUtility value^a^InstrumentTariffRespondent detailsHTA suitability1st line Nafees 2016 \[[@CR68]\]\
Metastatic NSCLC^b^PD vs BL state0.095TTON/APatients (but not NSCLC patients) from the general public in UK, Australia, France, China, S. Korea, TaiwanNoRES no side effects vs BL0.773SDis no side effects vs BL0.460 Chevalier 2013^c^ \[[@CR38]\]\
Advanced/metastatic NSCLC1 L PF0.69 (0.26)EQ-5DFrench (TTO)Stage I--Stage III/IV PF and PDMeets HAS requirements1 L PD0.61 (0.24) Chouaid 2013 \[[@CR39]\]\
Advanced/metastatic NSCLC1 L PF0.71 (0.24) (95% CI, 0.67--0.76)EQ-5D-3 LUKAt time of advanced diagnosis, mean age 64.8 years\
Adenocarcinoma: 65.2%\
Large-cell carcinoma: 6.8%\
SQ cell carcinoma: 17.1%\
Other: 9.9%\
Clinical stage at time of survey:\
IIIb: 17.9%\
IV: 82.1%Meets NICE requirements69.31 (18.33) (95% CI, 65.9--72.8)EQ-5D VASN/ANo1 L PD0.67 (0.2) (95% CI 0.59--0.75)EQ-5D-3 LUKMeets NICE requirements58.67 (17.4) (95% CI 51.3--66.0)EQ-5D VASN/ANo Iyer 2013 \[[@CR46]\]\
Advanced/metastatic NSCLCFrance, Germany 1 L0.63 (0.31)EQ-5DUK1Patients with:\
Adenocarcinoma: 56.3%\
Large-cell carcinoma: 11.8%\
SQ cell carcinoma: 29.3%\
Other: 2.5%\
Stage IIIb: 15.4%\
Stage: IV 84.6%Meets NICE requirement60.8 (19.9)EQ-5D VASN/ANo≥ 1st line Iyer 2013 \[[@CR46]\]\
Advanced/metastatic NSCLCFrance, Germany 1 L/2 L0.58 (0.35)EQ-5DUKPatients with:\
Adenocarcinoma: 56.3%\
Large-cell carcinoma: 11.8%\
SQ cell carcinoma: 29.3%\
Other: 2.5%\
Stage IIIb: 15.4%\
Stage: IV 84.6%Meets NICE and SMC requirementsFrance, 1 L/2 L0.57 (0.41)Germany, 1 L/2 L0.59 (0.31)France, Germany 1 L/2 L58.0 (19.9)EQ-5D VASNoFrance, 1 L/2 L57.1 (21.1)Germany, 1 L/2 L58.6 (19.1)2nd line Blackhall 2014 \[[@CR41]\]\
Advanced/metastatic ALK+ NSCLC2 L BL CRZ0.73 (0.24)EQ-5D-3 LNRMultinational patients, locally advanced/metastatic ALK+ NSCLC, 2 LUnclear as tariff NR2 L BL chemotherapy (PEM or DOC)0.70 (0.26)2 L BL PEM0.73 (0.24)2 L BL DOC0.67 (0.29)2 L on CRZ0.82 (SE, 0.01)\
(95% CI, 0.79--0.85)2 L on Chemotherapy0.73 (SE, 0.02)\
(95% CI, 0.70--0.77)2 L on PEM0.74 (SE, 0.02)\
(95% CI, 0.70--0.79)2 L on DOC0.66 (SE, 0.04)\
(95% CI, 0.58--0.74) Chevalier 2013^c^ \[[@CR38]\]\
Advanced/metastatic NSCLC2 L PF0.70 (0.22)EQ-5DFrench (TTO)Stage I--Stage III/IV PF and PDMeets HAS requirements2 L PD0.55 (0.35) Chouaid 2013 \[[@CR39]\]\
Advanced/metastatic NSCLC2 L PF0.74 (0.18)\
(95% CI, 0.68--0.80)EQ-5D-3 LUKAt time of advanced diagnosis, mean age 64.8 years\
Adenocarcinoma: 65.2%\
Large-cell carcinoma: 6.8%\
SQ cell carcinoma: 17.1%\
Other: 9.9%\
Clinical stage at time of survey:\
IIIb: 17.9%\
IV: 82.1%Meets NICE requirements65.0 (19.6)\
(95% CI, 59.2--70.8)EQ-5D VASN/ANo2 L PD0.59 (0.34)\
(95% CI, 0.42--0.77)EQ-5D-3 LUKMeets NICE requirements53.5 (23.3)\
(95% CI, 41.5--65.4)EQ-5D VASN/ANo Huang 2016^c^ \[[@CR45]\]\
Advanced PD-L1+ NSCLC2 L PF0.76 (95% CI, 0.75--0.77)EQ-5DNRMultinational patients with advanced NSCLC and PD-L1+ tumours in 2 L on PEMB or DOC, after platinum-based chemotherapyUnclear as tariff NR2 L PD0.69 (95% CI, 0.66--0.71)Advanced PD-L1+ NSCLC, 2 L, \>  360 days from death0.81 (0.79, 0.83)Patients with advanced NSCLC and PD-L1+ tumours in 2 L on PEMB or DOC, after platinum-based chemotherapyAdvanced PD-L1+ NSCLC, 2 L, 180--360 days from death0.73 (0.71, 0.75)Advanced PD-L1+ NSCLC, 2 L, 90--180 days from death0.69 (0.66, 0.72)Advanced PD-L1+ NSCLC, 2 L, 30--90 days from death0.60 (0.56, 0.64)Advanced PD-L1+ NSCLC, 2 L, \<  30 days from death0.40 (0.31, 0.48) Iyer 2013 \[[@CR46]\]\
Advanced/metastatic NSCLCOn treatment: 2 L only0.53 (0.38)EQ-5DUKFrench and German patientsMeets NICE and SMC requirements54.9 (19.3)EQ-5D VASN/ANo Langley 2013 \[[@CR48]\]\
Stage IV NSCLC with brain metastasesNSCLC with BM, previous tx allowed, OSC + WBRT 0 days0.63EQ-5DNR^d^UK and Australian NSCLC patients with brain metastasesNo, as VAS tariff usedNSCLC with BM, previous tx allowed, OSC + WBRT 28 days0.49NSCLC with BM, previous tx allowed, OSC + WBRT 56 days0.39NSCLC with BM, previous tx allowed, OSC + WBRT 112 days0.36NSCLC with BM, previous tx allowed, OSC + WBRT 168 days0.16NSCLC with BM, previous tx allowed, OSC alone 0 days0.60NSCLC with BM, previous tx allowed, OSC alone 28 days0.49NSCLC with BM, previous tx allowed, OSC alone 56 days0.44NSCLC with BM, previous tx allowed, OSC alone 112 days0.38NSCLC with BM, previous tx allowed, OSC alone 168 days0.36 Lloyd 2008 \[[@CR59]\]\
Cancer with chemotherapy-related anaemia or fatigueAnaemia, Hb level, ≥12.0 g/dL0.708 (95% CI, 0.057)SGN/AGeneral public sample from UKNo0.611 (95% CI, 0.112)TTOUK cancer patients who have recently experienced chemotherapy-related fatigue and anaemia completing vignette-based TTOMeets NICE/SMC requirements but still vignette-based health state rather than patient rating own health Nafees 2008 \[[@CR59]\]\
mNSCLC2 L Stable disease^e^0.65 (SE, 0.02)SGN/A100 members of general public in UKNo, but used in multiple HTA submissions2 L Responding disease^f^0.672 L Response gain0.02 (SE, 0.01)2 L Progressive disease^g^0.47 Novello 2015 \[[@CR49]\]\
Stage III/IV recurrent NSCLC (SQ and NSQ)^h^2 L NIN + DOC, before treatment (week 0)0.72EQ-5DUKMultinational patients with stage III/IV recurrent NSCLC (SQ and NSQ) in 2 L after chemotherapy\
Adenocarcinoma: 50.1%Meets NICE/SMC requirements2 L NIN + DOC, after treatment (week 30)0.612 L PLA + DOC, before treatment (week 0)0.722 L PLA + DOC, after treatment (week 30)0.622 L NIN + DOC, before treatment (week 0)69.0EQ-5D VASN/ANo2 L NIN + DOC, after treatment (week 30)63.22 L PLA + DOC, before treatment (week 0)69.02 L PLA + DOC, after treatment (week 30)63.1 Reck 2015 \[[@CR50]\]\
Advanced SQ NSCLC2 L NIVO at BL0.68 (0.208)EQ-5DNRMultinational patients with advanced SQ NSCLCUnclear as tariff NR2 L DOC at BL0.66 (0.284)2 L NIVO at BL63.7 (18.2)EQ-5D VASN/ANo2 L DOC at BL66.3 (20.5) Rudell 2016^c^ \[[@CR57]\]\
Advanced NSCLC, EGFR+2 L OSI at BL65.2 (20.33)EQ-5D-5 L VASN/AMultinational patients with EGFR+ advanced NSCLC, 2 L after previous TKINo2 L OSI at 36 weeks73.7 (17.33) Schuette 2012 \[[@CR51]\]\
NSCLC Stage IIIB--IV2 L, PEM at BL0.66 (0.256)EQ-5DUK TTOAustrian and German advanced/mNSCLC 2 L patients mainly after prior platinum treatment\
(IIIa, 6.7%; IIIb, 19.8%;\
IV, 73.5%)Meets NICE/SMC requirements2 L, PEM at 6 weeks (2nd cycle)0.02 (0.214)EQ-5D gain2 L, PEM at 6th cycle0.11 (0.228)2 L, PEM at BL59.3 (17.8)EQ-5D VASN/ANo2 L, PEM at 6 weeks (2nd cycle)3.3 (12.58)EQ-5D VAS gainN/A2 L, PEM at 6th cycle12.8 (17.62) Vargas 2009^c^ \[[@CR72]\]\
Advanced NSCLC2 L, on ERL0.81Global QoL indexNRPatients with advanced NSCLC, 2 L after previous chemotherapyNo2 L, on taxanes0.62≥ 2nd line Chen 2010^c^ \[[@CR73]\]\
Advanced NSCLC^d^2 L, DOC, during treatment0.45^i^SGN/AUK general public (as algorithm based on Nafees 2008 data used to calculate utilities)Acceptable data for SMC2 L, DOC, after treatment0.572 L, PEM, during treatment0.542 L, PEM, after treatment0.593 L, ERL, during treatment0.48BSC, during treatment0.47 Chevalier 2013 \[[@CR38]\]\
Advanced/metastatic NSCLC3/4 L PF0.61 (0.3)EQ-5DFrench (TTO)Stage I--Stage III/IV PF and PDMeets HAS requirements3/4 L PD0.42 (0.40) Griebsch 2014 \[[@CR37]\]\
Stage IIIb (with pleural effusion)/IV NSCLC adenocarcinoma\
(LUX-LUNG 1)^j^Week 4, progression effect longitudinal model−0.1EQ-5DUKMultinational advanced/metastatic NSCLC, 2 LLMeets NICE requirementsMixed effect longitudinal model IRC−0.056 (95% CI,\
− 0.083 to − 0.028)Mixed effect longitudinal model IN−0.065 (95% CI,\
− 0.092 to − 0.039)Mixed effect longitudinal model IRC, AFA−0.06Mixed effect longitudinal model IRC, BSC−0.046Mixed effect longitudinal model IINV, AFA−0.081Mixed effect longitudinal model IINV, BSC−0.033Week 4, progression effect longitudinal model−7.3EQ-5D VASN/ANoMixed effect longitudinal model IRC−3.76 (95% CI, −5.19 to −2.32)Mixed effect longitudinal model INV− 3.83 (95% CI, − 5.21 to − 2.44)Mixed effect longitudinal model IRC, AFA3.63Mixed effect longitudinal model IRC, BSC−4.11Mixed effect longitudinal model INV, AFA−4.42Mixed effect longitudinal model INV, BSC−2.55 Hirsh 2013 \[[@CR40]\]\
Stage IIIB/IV NSCLC3 LL on AFA + BSC0.71EQ-5DUK98% adenocarcinoma\
PD following treatment lines\
1--2, one of which was platinum based, plus PD after at least 12 weeks of ERL or GEFMeets NICE requirements3 LL on PLA + BSC0.673 LL on AFA + BSC67.4EQ-5D VASN/ANo3 LL on PLA + BSC65.2 Schwartzberg^c^ 2015 \[[@CR60]\]\
Stage IIIb/IV NSCLC (SQ & NSQ)All patients wk 61.0 (21.7)EQ-5D VASN/APatients, 2 LL, NIVO 3 mg/kg i.v. q2wNowk 125.8 (21.3)wk 188.2 (22.3)wk 248.2 (23.9)wk 308.4 (29.2)SDis wk 63.8 (19.8)wk 126.4 (21.9)wk 188.2 (20.9)wk 245.2(21.9)wk 307.2 (28.5)PR wk 67.3 (22.4)wk 126.6 (24.7)wk 188.1 (27.6)wk 2418.1 (31.0)wk 3013.7 (38.2)PD wk 6−5.8 (21.1)wk 12−3.0 (19.8)wk 183.9 (24.3)wk 246.8 (12.2)wk 305.5 (15.7)Treatment line not specified Bradbury 2008^c^ \[[@CR42]\]\
Advanced NSCLCOn ERL0.772EQ-5DNR (possibly Canadian)Canadian patientsPotentially relevant to CADTHOn BSC0.754 Chang 2016^c^ \[[@CR63]\]\
Advanced NSCLC\> 360 days from death0.904\
(95% CI, 0.892--0.917)TTONRGeneral public, South KoreaNo180--360 days from death0.720\
(95% CI, 0.692--0.748)90--180 days from death0.627\
(95% CI, 0.598--0.655)30--90 days from death0.379\
(95% CI, 0.349--0.409)\< 30 days from death0.195\
(95% CI, 0.172--0.218) Dansk 2016^c^ \[[@CR43]\]\
Advanced NSCLCSynthesized PFMedian, 0.706\
Range, 0.620--0.815Synthesized utility across \> 1 instrument typeNRUtilities synthesized included those where respondents were patients and those where they were the general public considering a hypothetical health stateNoSynthesized PF trial-basedMedian, 0.750\
Range, 0.627--0.815Synthesized PF non-trial-basedMedian, 0.653\
Range, 0.620--0.653Synthesized PDMedian, 0.565\
Range, 0.470--0.688Synthesized PD trial-basedMedian, 0.599\
Range, 0.550--0.688Synthesized PD non-trial-basedMedian, 0.473\
Range, 0.470--0.530 Doyle 2008 \[[@CR65]\]\
Metastatic NSCLCSDis, no additional symptoms0.626SGN/AGeneral publicNoTreatment response, no additional symptoms0.712 Grunberg 2009^c^ \[[@CR58]\]\
BC/LCChemotherapy-induced nausea and vomiting of differing severityReported graphicallySGN/APatients BC/LCMeets NICE requirements Grutters 2010^c^ \[[@CR44]\]\
NSCLC (stage unspecified)NSCLC with grade 3+ dyspnoea, stage unspecifiedMedian, 0.52EQ-5D-5 LNRPatients at an early treatment stageNo Jang 2010 \[[@CR47]\]\
Stage IV NSCLCStage IV NSCLC0.75 (0.15)EQ-5DUSPatients with NSCLC attending a major Canadian cancer center outpatient clinicNo Linnet 2015^c^ \[[@CR62]\]\
Stage IV NSCLC on oral VINOPCS, cycle 237.0SF-12N/APatientsNoPCS, cycle 338.6MCS, cycle 247.7MCS, cycle 344.2PCS, cycle 252.9CaregiversPotential to estimate SF-6D for caregivers to mNSCLC patients, for SMC or CADTHPCS, cycle 353.4MCS, cycle 246.2MCS, cycle 344.6 Lloyd 2005^c^ \[[@CR66]\]\
Stage IV NSCLCRES0.70SG^k^N/AGeneral publicNoSDis, oral treatment0.63SDis, i.v. treatment0.58PD0.42End of life0.33 Manser 2006 \[[@CR61]\]\
Stage IV NSCLCStage IVMedian, 0.68\
(IQR, 0.54--0.82)AQoLAustraliaMixed stage enrolled:\
I, 31.5%; II, 17.4%; IIIa, 16.3%; IIIb, 7.6%; IV, 25.0%No Matza 2014 \[[@CR67]\]\
Stage IV cancer with bone metastasesCancer with bone metastases and no SRE0.47 (0.41)TTON/AGeneral public, UK\
(Edinburgh and London)No0.47 (0.45)General public, Canada\
(Montreal and Toronto)0.47 (0.42)General public, UK and Canada Stewart 2015 \[[@CR56]\]\
EGFR+ Stage IV NSCLCPR/SDis on EGFR TKIs (GEF, ERL, AZD9291)0.82 (SE, 0.16)EQ-5D-3 LNRPatients, eligible for or on TKI tx, 55% Asian, 45% male, median age 60, 66% never smokers. Stage IV:\
at diagnosis, 80%\
when surveyed, 100%UnclearResponded to standard chemotherapy0.80 (SE, 0.12)EGFR+, responded to GEF0.84 (SE, 0.14)EGFR+, responded to ERL0.82 (SE, 0.17)EGFR+, responded to AZD92910.83 (SE, 0.16)EGFR+, PD during TKI treatment (GEF, ERL, AZD9291)0.74 (SE, 0.08)EGFR+, all patients (PR/SDis/PD), 25% 3LL0.802 Tabberer 2006 \[[@CR52]\]\
Advanced NSCLCRES0.49EQ-5DNRGeneral public, UK\
(Cardiff, Glasgow, London and Oxford)NoSDis0.46SDis + oral treatment0.45SDis + i.v. treatment0.43PD0.22Near death0.15 Trippoli 2001 \[[@CR53]\]\
Metastatic NSCLCMetastatic NSCLC0.53 (0.36)EQ-5DUK (TTO)Italian patientsMeets NICE and SMC reference cases0.55 (0.22)^l^EQ-5D VASN/ANo Yang 2014 \[[@CR54]\]\
Stage IIIB/IV NSCLCStage IV inoperable, performance status 0--10.75 (0.22)EQ-5DTaiwanPatients, mixed NSCLC stages: I, 0.8%; II, 0%; IIIA, 4.5%; IIIB, 16.9%; IV, 77.8%NoStage IV inoperable, performance status 0--40.75 (0.22) Yokoyama 2013^c^ \[[@CR55]\]\
Advanced NSCLC/SCLCStage IIIB/IV NSCLC/SCLC with bone metastasis and SRENREQ-5DNRPatients, advanced NSCLC, 72%, SCLC, 28%\
NSCLC and SCLC: IIIB, 37%; IV, 63%No^a^Mean, or mean (SD) unless stated otherwise^b^VAS scores were also reported in this study but unclear whether this was EQ-VAS^c^These studies were published as abstracts or posters^d^This referenced article (https://www.ncbi.nlm.nih.gov/pubmed/10109801) is for a VAS valuation^e^ *SDis vignette:*• You have a life-threatening illness that is stable on treatment. You are receiving cycles of treatment that require you to go to the outpatient clinic• You have lost weight, and your appetite is reduced. You sometimes experience pain or discomfort in your chest or under your ribs, which can be treated with painkillers. You have shortness of breath, and breathing can be painful. You have a persistent nagging cough• You are able to wash and dress yourself and do jobs around the home. Shopping and daily activities take more effort than usual• You are able to visit family and friends but often have to cut it short because you get tired• You sometimes feel less physically attractive than you used to. Your illness has affected your sex drive• You worry about dying and how your loved ones will cope^f^ *Second-line responding vignette:*• You have a life-threatening illness that is responding to treatment. You are receiving cycles of treatment which require you to go to the outpatient clinic• You are gaining back your weight and your appetite is returning. You occasionally experience pain or discomfort in your chest or under your ribs which can be treated with painkillers. You sometimes have shortness of breath. You occasionally have a nagging cough• You are able to wash and dress yourself and do jobs around the home. Shopping and daily activities can sometimes be tiring• You are able to visit family and friends but sometimes have to cut it short because you get tired• You occasionally feel less physically attractive than you used to. Your illness has somewhat affected your sex drive• You sometimes worry about dying and how your loved ones will cope^g^ *Second-line PD vignette:*• You have a life-threatening illness, and your condition is getting worse• You have lost your appetite and have experienced significant weight loss. You experience pain and discomfort in your chest or under your ribs. You frequently have shortness of breath, and breathing is often painful. You have a persistent nagging cough and sometimes cough up blood. You may experience some difficulty swallowing• You experience severe fatigue and feel too tired to go out or to see family and friends. It has affected your relationships with them• You need assistance to wash and dress yourself. You are often unable to do jobs around the house or other daily activities. You are dependent on others to do your shopping and are unable to do your usual daily activities• You often feel less physically attractive than you used to. You have little or no sexual drive• You are depressed, and dying is always on your mind. You worry about how your loved ones will cope^h^This study also has utilities available every 3 weeks between week 0 and week 30 for all treatments^i^All utilities in this paper assumed to be the mean, although it is not clearly stated in the paper^j^1 L data also reported from LUX-LUNG 3^k^Individual country values are also available in this publication^l^This value is reported as in the original publication*Abbreviations: 1 L* first line, *2 L* second line, *2 LL* second and subsequent line, *3 LL* third and subsequent line, *AFA* afatinib, *ALK+* anaplastic lymphoma kinase mutation positive, *AQoL* Assessment of Quality of Life instrument, *BC* breast cancer, *BL* baseline, *BSC* best supportive care, *CADTH* Canadian Agency for Drugs and Technologies in Health, *CI* confidence interval, *CRZ* crizotinib, *DOC* docetaxel, *EGFR* epidermal growth factor receptor, *EGFR+* epidermal growth factor receptor mutation positive, *EORTC QLQ* European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire, *EQ-VAS* EuroQol visual analogue scale, *ERL* erlotinib, *GEF* gefitinib, *HAS* Haute Autorité de Santé, *HTA* health technology assessment, *IQR* interquartile range, *i.v.* intravenous, *LC* lung cancer, *MCS* mental component summary, *mNSCLC* metastatic non-small cell lung cancer, *N/A* not applicable, *NICE* National Institute for Health and Care Excellence, *NIN* nintedanib, *NIVO* nivolumab, *NR* not reported, *NSCLC* non-small cell lung cancer, *NSQ* non-squamous, *NTS* not treatment-specific, *OSC* optimal standard care, *OSI* osimertinib, *PCS* physical component summary, *PD* progressive disease, *PEM* pemetrexed, *PF* progression-free, *PLA* placebo, *PR* partial response, *PSS* progression-status specific, *q2w* once every 2 weeks, *QoL* quality of life, *RES* response, *SCLC* small-cell lung cancer, *SD* standard deviation, *SDis* stable disease, *SE* standard error, *SF-6D* 6-dimension Short-Form Health Survey, *SF-12/36* 12-/36-item Short-Form Health Survey, *SG* standard gamble, *SMC* Scottish Medicines Consortium, *SQ* squamous, *SRE* skeletal-related event, *TKI* tyrosine kinase inhibitor, *TTO* time trade-off, *VAS* visual analogue scale, *VINO* vinorelbine, *WBRT* whole-brain radiotherapy

Disutilities for progression from a stable state were − 0.056 or − 0.065 by EQ-5D, both from Griebsch et al. \[[@CR37]\], or − 0.1798 by general population-derived SG \[[@CR69]\]. Overall, HSUVs varied not only by treatment line and disease state, but also by the treatment received under the same health state (potentially reflecting differences in safety profiles) and by the instrument/tariff used to derive the HSUV.

Relevant disutilities and decrements {#Sec11}
------------------------------------

Eleven studies identified in this systematic review reported disutilities or decrements for AE health states \[[@CR44], [@CR52], [@CR55], [@CR58], [@CR59], [@CR65], [@CR67]--[@CR71]\]. Only two studies reported disutilities specifically associated with second-line treatment \[[@CR69], [@CR71]\], and another two studies did not specify the treatment line \[[@CR44], [@CR65]\]; disutility and decrement data are summarized in Table [4](#Tab4){ref-type="table"}. Utility-incorporating decrements were identified for the following AEs in the context of second-line "stable disease" or second-line "responding": diarrhoea, fatigue, febrile neutropenia, hair loss and nausea/vomiting. Disutilities associated with second-line treatment were reported for the following events \[[@CR69]\]: "moving from stable to progressive state" (− 0.18), neutropenia (− 0.09), febrile neutropenia (− 0.09), fatigue (− 0.07), nausea/vomiting (− 0.05), diarrhoea (− 0.05), hair loss (− 0.04) and rash (− 0.03).Table 4Disutilities and decrements for adverse event health states in patients with previously treated mNSCLCRelevanceAuthor, year, country, reference^a^Instrument and respondentUtility typeHealth state/disutilityMean HSUV (SD) \[SE\] {95% CI}HTA suitabilityAdvanced/mNSCLCNafees 2008, UK \[[@CR69]\]SG\
General publicUIDStage IV NSCLC, 2 L, stable diseaseDoes not meet HTA body reference case as vignette-based utility completed by general public respondents. Has been used in multiple HTA submissions, however. Specifically 2 L and UK, good sample size (*n*=100) and measure of dispersion available.+ Diarrhoea0.61+ Fatigue0.58+ Febrile neutropenia0.56+ Hair loss0.61+ Nausea/vomiting0.61+ Neutropenia0.56+ Rash0.62Stage IV NSCLC, 2 L, responding disease+ Diarrhoea0.63+ Fatigue0.60+ Febrile neutropenia0.58+ Hair loss0.63+ Nausea/vomiting0.62+ Neutropenia0.58+ Rash0.64DStage IV NSCLC, 2 L,\
moving from stable to progressive−0.18 \[0.022\]Neutropenia−0.09 \[0.015\]Febrile neutropenia−0.09 \[0.016\]Fatigue−0.07 \[0.018\]Nausea and vomiting−0.05 \[0.016\]Diarrhoea−0.05 \[0.016\]Hair loss−0.04 \[0.015\]Rash−0.03 \[0.012\]Response gain0.02 \[0.007\]Tabberer 2006, UK \[[@CR52]\]EQ-5D (tariff NR but likely UK TTO tariff as UK sample)\
General publicDCompared with stable disease (advanced NSCLC, line not specified)Not suitable as general public respondents, line of treatment not specified, and no measure of dispersion reported. Good sample size, however (*n*=154) and Nafees et al. 2008 in 2 L does not provide disutilities for neuropathy or stomatitis so these values from Tabberer et al. may be the best available.Febrile neutropenia−0.27Rash−0.06Neuropathy−0.15Neutropenia−0.14Nausea−0.14Stomatitis−0.14Diarrhoea−0.13Doyle 2008, UK \[[@CR65]\]SG\
General publicUIDMetastatic NSCLC, line not specified, SDis no additional symptomsDoes not meet reference case as general public respondents. However, these are the only disutilities for severe symptoms for cough, dyspnoea and pain in mNSCLC, so are best option in spite of not meeting HTA derivation method preferences (*n*=101)+ Cough0.58+ Dyspnoea0.58+ Pain0.56+ Cough, dyspnoea and pain0.46DCough−0.05 \[0.011\]Dyspnoea−0.05 \[0.012\]Pain−0.07 \[0.012\]Cough, dyspnoea and pain^c^*− 0.17* ^b^Responding disease gain vs SDis0.09 \[0.015\]As line not specified, data from Nafees et al. 2008 should be used in preference.Handorf 2012, USA \[[@CR70]\]Expert opinionUIDStage IV NSCLC adenocarcinoma (1 L SDis)+ neutropenia0.67Does not meet reference case as expert opinion-derived. This AE is covered by Nafees et al. 2008, which uses a better derivation method than expert opinion.+ pneumothorax0.63Does not meet reference case as expert opinion-derived, but these are the only estimates for these AE health states. SDis estimate was 0.670 (oral therapy) and 0.653 (i.v. chemotherapy) for disutility calculation.+ haemorrhage0.63+ thrombocytopenia0.65+ thrombosis0.56Earlier stage NSCLC (curative intent)Grutters 2010, country NR \[[@CR44]\]EQ-5D-5 L (tariff NR)\
PatientsUIDNSCLC, curative intent stage, line not specified, grade III+ dyspnoea0.52 (median)Patient-derived EQ-5D but tariff and measure of dispersion NR. Only source of grade III+ dyspnea. Utility for NSCLC patients without dyspnoea in this sample was 0.81, i.e. disutility − 0.29Advanced/mLC (NSCLC+SCLC)Yokoyama 2013, Japan \[[@CR55]\]EQ-5D (tariff NR)\
PatientsDStage IIIB/IV NSCLC/SCLC with bone metastases + skeletal related event (pathologic fracture, radiation or surgery to bone lesion, spinal cord compression or hypercalcaemia)− 0.05^d^Provides NSCLC/SCLC (mixed) patient-derived EQ-5D decrement for (mixed) SREs. Data for these AEs are limited, so although this estimate is not robust (n=9 and response % low at 32%) it does provide an indication. No variability measure reportedBreast cancer and lung cancerGrunberg 2009, USA \[[@CR58]\]SG\
PatientsUIDBase state: continuous nausea and vomiting0.53^f^Nafees et al. 2008 provide data for nausea and vomiting but if different levels of nausea and vomiting need to be discerned then these utilities can be considered. Patient-derived SG but mixed lung/breast cancers. Good sample size (*n*=96) but no measure of dispersion. As the Copyright fee for Grunberg 2009 was high, these data are reported from Shabaruddin 2013 \[79\] (a previous SR that extracted the graphical data from Grunberg 2009)IncrementLimited nausea and limit vomiting vs continuous nausea and vomiting+ 0.53^f^IncrementLimited nausea vs continuous nausea and vomiting+ 0.55^f^IncrementLimited vomiting vs continuous nausea and vomiting+ 0.50^f^Advanced CancerMatza 2014, UK \[[@CR67]\]TTO\
General publicUStage IV cancer with bone metastases (no skeletal-related events)0.47 (0.41)Does not meet reference case as general population respondents. However, as there are no alternative utilities for bone metastases these UK utilities could be considered for NICE or SMC. Good sample size (*n*=126), SD available.UID+ spinal cord compression without paralysis0.25 (0.50)+ spinal cord compression with paralysis0.13 (0.49)+ fracture of the leg0.42 (0.41)+ fracture of the rib0.44 (0.42)+ fracture of the arm0.44 (0.41)+ radiation treatment (2 weeks, 5 appointments/week)0.42 (0.42)+ radiation treatment (2 appointments)0.45 (0.41)+ surgery to stabilize bone0.40 (0.44)Matza 2014, Canada \[[@CR67]\]TTO\
General publicUStage IV cancer with bone metastases (no skeletal-related events)0.47 (0.45)Does not meet reference case as general population respondents. However, as there are no alternative utilities for bone metastases these Canadian utilities could be considered for CADTH. Reasonable sample size (*n*=61), SD available.UID+ spinal cord compression without paralysis0.25 (0.54)+ spinal cord compression with paralysis0.19 (0.53)+ fracture of the leg0.40 (0.48)+ fracture of the rib0.43 (0.47)+ fracture of the arm0.43 (0.48)+ radiation treatment (2 weeks, 5 appointments/week)0.41 (0.50)+ radiation treatment (2 appointments)0.45 (0.45)+ surgery to stabilize bone0.39 (0.50)Matza 2014, UK and Canada \[[@CR67]\]TTO\
General publicUStage IV cancer with bone metastases (no skeletal-related events)0.47 (0.42)Does not meet reference case as general population respondents. However, as there are no alternative utilities for bone metastases these UK+Canadian utilities could be considered for NICE, SMC or CADTH. Good sample size (*n*=187), SD available.UID+ spinal cord compression without paralysis0.25 (0.21)+ spinal cord compression with paralysis0.15 (0.50)+ fracture of the leg0.41 (0.43)+ fracture of the rib0.44 (0.43)+ fracture of the arm0.43 (0.43)+ radiation treatment (2 weeks, 5 appointments/week)0.41 (0.45)+ radiation treatment (2 appointments)0.45 (0.42)+ surgery to stabilize bone0.40 (0.46)Matza 2014, UK \[[@CR67]\]TTO\
General publicDStage IV cancer with bone metastasesAs above+ spinal cord compression without paralysis−0.22 (0.31)+ spinal cord compression with paralysis−0.34 (0.36)+ fracture of the leg−0.05 (0.09)+ fracture of the rib−0.03 (0.08)+ fracture of the arm−0.03 (0.07)+ radiation treatment (2 weeks, 5 appointments/week)−0.05 (0.12)+ radiation treatment (2 appointments)−0.02 (0.07)+ surgery to stabilize bone−0.07 (0.17)Matza 2014, Canada \[[@CR67]\]TTO\
General publicDStage IV cancer with bone metastasesAs above+ spinal cord compression without paralysis−0.22 (0.32)+ spinal cord compression with paralysis−0.28 (0.30)+ fracture of the leg−0.07 (0.19)+ fracture of the rib−0.04 (0.17)+ fracture of the arm−0.04 (0.07)+ radiation treatment (2 weeks, 5 appointments/week)−0.06 (0.21)+ radiation treatment (2 appointments)−0.02 (0.11)+ surgery to stabilize bone−0.08 (0.21)Matza 2014, UK and Canada \[[@CR67]\]TTO\
General publicDStage IV cancer with bone metastasesAs above+ spinal cord compression without paralysis−0.22 (0.31)+ spinal cord compression with paralysis−0.32 (0.34)+ fracture of the leg−0.06 (0.13)+ fracture of the rib−0.03 (0.12)+ fracture of the arm−0.04 (0.11)+ radiation treatment (2 weeks, 5 appointments/week)−0.06 (0.15)+ radiation treatment (2 appointments)−0.02 (0.08)+ surgery to stabilize bone−0.07 (0.18)Cancer, unclear stageLloyd 2008, UK \[[@CR59]\]SG\
General publicUIDAnaemia associated with cancer treatmentDoes not meet reference case as general population sample respondent for SG exercise.Haemoglobin level (g/dL)7.0--8.00.58 {0.067}8.0--9.00.61 {0.064}9.0--10.00.64 {0.060}10.0--10.50.64 {0.062}10.5--11.00.66 {0.061}11.0--12.00.70 {0.056}\>12.00.71 {0.057}VAS\
General publicUIDHaemoglobin level (g/dL)7.0--8.016.9 {2.6}8.0--9.022.3 {3.0}9.0--10.027.6 {2.9}10.0--10.532.9 {3.4}10.5--11.038.8 {3.6}11.0--12.045.9 {4.2}\>12.051.2 {4.3}TTO\
Cancer patients with recent experience of chemotherapy-related anaemia or fatigueUIDHaemoglobin level (g/dL)7.0--8.00.30 {0.127}8.0--9.00.36 {0.126}9.0--10.00.41 {0.125}10.0--10.50.45 {0.122}10.5--11.00.45 {0.111}11.0--12.00.55 {0.105}\>12.00.61 {0.112}UOwn current health0.85 {0.034}EQ-5D current health0.87 {0.076}VAS\
Cancer patients with recent experience of chemotherapy-related anaemia or fatigueUIDHaemoglobin level (g/dL)7.0--8.021.7 {5.7}8.0--9.032.4 {6.6}9.0--10.034.2 {6.7}10.0--10.541.9 {6.6}10.5--11.044.7 {6.6}11.0--12.052.2 {6.8}\>12.062.4 {7.9}UOwn current health87.6 {4.9}EQ-5D current health84.2 {4.57}NRWestwood 2014, NR \[[@CR71]\]NRDAnaemia0.073 \[0.018\]Disutilities for anaemia and treatment mode have been used in previous NICE submissions. However, there is no information concerning their derivation.2 L NSCLCOral therapy (ERL)0.014 \[0.012\]2 L NSCLCi.v. therapy0.043 \[0.020\]Patients without NSCLC\
1 L settingNafees 2016, Multinational and UK \[[@CR68]\]^g^TTO\
Patients (but not NSCLC patients) from the general public in UK, Australia, France, China, S. Korea, TaiwanDBleeding vs BL (stable no side effects)−0.25NoHypertension vs BL (stable no side effects)−0.03UIDResponding + bleeding vs BL0.534Responding + hypertension vs BL0.749Stable + bleeding vs BL0.508Stable + hypertension vs BL0.729^a^Some studies identified in this systematic review were not included in this table for the following reasons: Grunberg 2009 \[[@CR58]\] and Grutters 2010 \[[@CR44]\] did not report values^b^The italics indicate a calculated utility. This is calculated from the values reported in Doyle 2008 \[[@CR65]\] Table [3](#Tab3){ref-type="table"} (difference between stable disease no other symptoms and stable disease with cough, dyspnoea and pain, to obtain the disutility). It is not calculated by adding the disutilities, as this would not be valid^c^Values were calculated from 'SDis + cough, dyspnea and pain' utility minus 'SDis no additional symptoms' utility^d^The study did not indicate if mean or median^e^Some studies identified in this systematic review were not included in this table for the following reasons: Grunberg 2009 \[[@CR58]\] and Grutters 2010 \[[@CR44]\] did not report values, and Nafees 2016 \[[@CR68]\] reported variation in two decrements (bleeding, hypertension) based on the different populations in which valuation was undertaken^f^As reported in Shabarruddin 2013 \[[@CR79]\], base state and utility increments were presented on different scales: base state was based on standard gamble scale between perfect health (arbitrary score of 100) or immediate death (arbitrary score of 0) while the utility increments were based on a scale between perfect health (arbitrary score of 100) and the surrogate negative anchor of continuous nausea/vomiting (re-set to an arbitrary score of 0)^g^Values are presented for global population (United Kingdom, Australia, France, China, Taiwan, Korea). Note that country-specific data are also available*Abbreviations: 1 L* first line, *BL* baseline, *CI* confidence interval, *D* decrement, *ERL* erlotinib, *HSUV* health state utility value, *HTA* health technology assessment, *i.v.* intravenous, *LC* lung cancer, *mLC* metastatic lung cancer, *mNSCLC* metastatic non-small cell lung cancer, *NICE* National Institute for Health and Care Excellence, *NR* not reported, *NSCLC* non-small cell lung cancer, *SCLC* small cell lung cancer, *SD* standard deviation, *SE* standard error, *SG* standard gamble, *TTO* time trade-off, *U* utility, *UID* utility incorporating decrement for adverse events, *VAS* visual analogue scale

Further recommended sources of AE health state (dis) utilities were as follows (Fig. [1](#Fig1){ref-type="fig"}): in 2 L from general population SG in Nafees et al. 2008 \[[@CR69]\]; in metastatic NSCLC (line unspecified) from general population SG in Doyle et al. 2008 \[[@CR65]\]; in 1 L from patients without NSCLC using directly elicited TTO in Nafees et al. 2016 \[[@CR68]\]; in 2 L in NSCLC as reported in Westwood et al. 2014 \[[@CR71]\]; in cancer with bone metastases for skeletal-related events from general population TTO in Matza et al. 2014 \[[@CR67]\]; stage IV NSCLC in 1 L from expert opinion estimates in Handorf et al. 2012 (expert-opinion-derived utilities from this study were included, as they are the only source of estimates for pneumothorax, thrombocytopenia and thrombosis disutilities) \[[@CR70]\]; and anaemia from general population SG or from patient-derived TTO in Lloyd et al. 2008 \[[@CR59]\].

Description of HTA-relevant HSUVs and disutilities {#Sec12}
--------------------------------------------------

Of the 36 publications, 13 provided HSUVs that meet the NICE reference case or are considered acceptable to the HTA agencies of interest \[[@CR37]--[@CR40], [@CR42], [@CR45], [@CR46], [@CR49], [@CR53], [@CR56], [@CR58], [@CR64], [@CR69]\], based on the measurement technique for generation of HSUVs, as outlined in Additional file [3](#MOESM3){ref-type="media"}: Figure S1. The main characteristics of these studies are presented in Table [3](#Tab3){ref-type="table"}. These 13 publications reported data from multinational studies \[[@CR37]--[@CR40], [@CR45], [@CR49], [@CR64]\], and from Canada \[[@CR42], [@CR56]\], France/Germany \[[@CR46]\], USA \[[@CR58]\], Italy \[[@CR53]\] and the UK \[[@CR69]\]. In these studies, HRQoL was measured using EQ-5D \[[@CR37]--[@CR40], [@CR42], [@CR45], [@CR46], [@CR49], [@CR53], [@CR56]\], EQ-VAS \[[@CR37], [@CR39], [@CR40], [@CR49]\] and SG \[[@CR58], [@CR64], [@CR69]\]. The HTA suitability of disutilities and decrements for AE health states in previously treated patients are reported in Table [4](#Tab4){ref-type="table"}.

Discussion {#Sec13}
==========

Economic evaluation, particularly cost--utility analysis, provides important information for guiding decision-making in health care, and its use in HTA is increasing globally. Such evaluation includes examination of the time spent in different disease states and uses an HSUV for each disease state to calculate QALYs; HSUVs therefore play a key role in economic evaluation. As summarized in Additional file [3](#MOESM3){ref-type="media"}: Figure S1, NICE, SMC, CADTH, HAS and PBAC prefer utilities to be estimated using a generic preference-based instrument, with health states described by patients through use of a questionnaire, and with the health state valued using a country-specific tariff that reflects societal preferences. As the aim of this systematic review was to evaluate the experience of adults with previously treated mNSCLC, the synthesis of health state utility estimates was outside its scope. However, the findings presented here may provide a basis for generation of an accurate estimate of the mean HSUV for use in economic evaluations \[[@CR74], [@CR75]\].

This systematic review identified HSUVs relevant to the experience of previously treated adult patients with mNSCLC. Search strings were designed to allow (dis) utilities from a broader population (including lung cancer, advanced/metastatic cancer and specific metastases common in patients with lung cancer). In the absence of second-line mNSCLC (dis) utilities, alternatives were selected with decreasing population specificity and relevance from first-line mNSCLC, NSCLC, lung cancer or advanced/metastatic cancer, as outlined in Fig. [1](#Fig1){ref-type="fig"}. Ordering the HSUVs by line of treatment reflects the practice of switching treatment at progression. However, for the newer immunotherapies, patients may remain on treatment post-progression, and their HRQoL may remain at pre-progression levels. Thus, HSUVs estimated for progression status-specific health states from patients receiving chemotherapy may not be suitable to apply to the equivalent health states when patients receive immunotherapy.

In total, the 36 identified articles reported 591 HSUVs relevant to the experience of previously treated adult patients with mNSCLC, and 11 of these studies reported a total of 195 disutilities or decrements for AE health states that are relevant to the experience of patients with mNSCLC. The range of HSUVs identified for comparable health states, such as progression-free/stable disease among patients treated second-line for advanced/metastatic NSCLC \[[@CR39], [@CR45]\], highlights how differences in study type, tariff, health state and the measures used can drive variation in HSUV estimates. For instance, disutilities for progression from a stable state were − 0.056 or − 0.065 using EQ-5D, \[[@CR37]\] or − 0.1798 by general-population-derived SG. \[[@CR69]\] To overcome such variations, where possible, HSUV studies should seek to use instruments, respondents and valuation populations that are most acceptable to HTA bodies. However, there are instances where variation in methods can be justified. For example, disutility values derived from vignettes and a general public sample were used by Nafees et al. \[[@CR69]\], because asking patients suffering such toxicities to complete HRQoL questionnaires was considered to be too burdensome for patients and potentially unethical. Moreover, although the variation may be large, it helps decision makers to identify where variability exists and informs the design of sensitivity analyses.

In the 36 publications identified, 13 provided HSUVs that meet the NICE reference case or are considered acceptable to the HTA agencies of interest \[[@CR37]--[@CR40], [@CR42], [@CR45], [@CR46], [@CR49], [@CR53], [@CR56], [@CR58], [@CR64], [@CR69]\]. These were deemed suitable because HRQoL was measured using the EQ-5D \[[@CR37]--[@CR40], [@CR42], [@CR45], [@CR46], [@CR49], [@CR53], [@CR56]\] or SG \[[@CR58], [@CR64], [@CR69]\], both measures preferred or accepted by several HTA authorities. This endeavour fills an important gap in the field because hitherto, only two reports had described HSUVs in mNSCLC \[[@CR68], [@CR69]\]; neither was a systematic review of the literature, nor did they assess their appropriateness for use in economic evaluations.

This systematic review did not identify an HSUV report based on data from the OAK trial (NCT02008227), because it was published as a congress abstract after the cut-off date for literature searching \[[@CR76]\]. However, the HSUVs are relevant to the aims of this systematic review, and a brief description is provided below for completeness. Patients with locally advanced NSCLC or mNSCLC after failure of platinum-containing chemotherapy were randomized in a phase 3 trial to receive atezolizumab or docetaxel \[[@CR76], [@CR77]\]. As part of the trial, patients completed the EQ-5D, and the resultant HSUVs were presented by time point before death. This study is similar to Huang et al. 2016, which also presented time-to-death EQ-5D utilities for a similar patient group receiving immunotherapy, except comparing pembrolizumab and docetaxel \[[@CR45]\]. Overall, HSUVs were very similar between studies at approximately equivalent time points. In the OAK study, the following HSUVs were reported by time point before death: 0.77 (\> 210 days), 0.71 (105--210 days), 0.61 (35--105 days) and 0.39 (\< 35 days). For comparison, HSUVs published by Huang et al. 2016 were 0.73 (180--360 days), 0.69 (90--180 days), 0.60 (30--90 days) and 0.40 (\< 30 days). A further study evaluating the efficacy of immunotherapy in patients with NSCLC showed that baseline mean EQ-VAS and EQ-5D index scores were similar for nivolumab (63.7 and 0.68, respectively) and docetaxel (66.3 and 0.66, respectively) \[[@CR50]\].

Strengths of this systematic review include the wide range of data sources searched and the search string design, which enabled identification of disutilities and utility decrements for a wide range of AEs and progressive disease states (e.g. common sites of metastasis from lung cancer) of relevance to the experience of patients previously treated for mNSCLC. We have presented HSUVs by line of treatment, allowing use in economic modelling, and have discussed HSUVs likely to be accepted by the HTA bodies of interest. Inadequate or inconsistent reporting is common, and low sample sizes and response rates considerably impact on the reported confidence intervals of the reported results. However, among the studies identified here, most reported sample size (over 100 respondents in most cases), many provided a measure of variability for the values reported, and several were based on response rates greater than 80% (although response rates were unreported in more than half of the studies). Moreover, the use of only published HSUVs can be a limitation, as HTA submissions may use HSUVs that have not been previously published. As part of this systematic review, we have therefore searched HTA submissions for any relevant utilities; most HTAs use data reported by Nafees et al. \[[@CR69]\]

Limitations of this review include that the label for the upper bound of the utility scale (e.g. "full health" or "perfect health") was not recorded. This has been shown to be a significant predictor of utility in lung cancer \[[@CR78]\], so variation in utilities due to a different upper bound label cannot be explored. A further limitation concerns data extraction from some studies presented as congress abstracts or posters. Owing to the word restrictions placed on conference proceedings they may not be considered a robust data source in comparison with full publications. Furthermore, both screening and data extraction were conducted primarily by a single reviewer, and only 50% of studies were checked by a second reviewer. The exclusion of studies that used mapping to derive EQ-5D and utility values is a further limitation of this study; however, sufficient data obtained through direct measurement were identified to be informative.

Conclusions {#Sec14}
===========

This systematic review begins to address the challenge of identifying reliable estimates of utility values in mNSCLC that are suitable for use in economic evaluations. Our work has also highlighted that these estimates are vulnerable to variations in study type, tariff, health state and the measures used, and that shortcomings in reporting are common.
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================

 {#Sec15}

Additional file 1:**Table S1.** Search strings. (DOCX 90 kb) Additional file 2:**Table S2.** Listing of first-line mNSCLC studies with utility data excluded at second pass \[[@CR80]--[@CR100]\]. (DOCX 84 kb) Additional file 3:**Figure S1.** Hierarchy of preferred methodology for generation of HSUVs for different HTA agencies. (PDF 1172 kb) Additional file 4:**Table S3.** Quality assessment of identified studies. (DOCX 111 kb)

AE

:   Adverse event

AQoL

:   Assessment of Quality of Life instrument

CADTH

:   Canadian Agency for Drugs and Technologies in Health
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:   Haute Autorité de Santé

HRQoL

:   Health-related quality of life

HSUV

:   Health state utility value

HTA

:   Health technology assessment

mNSCLC

:   Metastatic non-small cell lung cancer

NICE

:   National Institute for Health and Care Excellence

NSCLC

:   Non-small cell lung cancer

PBAC

:   Australian Pharmaceutical Benefits Advisory Committee

PICOS

:   Patient, intervention, comparator, outcome, study

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

QALY

:   Quality-adjusted life-year

RECIST

:   Response Evaluation Criteria in Solid Tumors

SF-12/SF-36

:   12-/36-item Short-Form Health Survey

SF-6D

:   6-dimension Short-Form Health Survey

SG

:   Standard gamble

SMC

:   Scottish Medicines Consortium

TTO

:   Time trade-off

VAS

:   Visual analogue scale
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